<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101626570</journal-id>
<journal-id journal-id-type="pubmed-jr-id">42290</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Behav Neurosci Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Behav Neurosci Rep</journal-id>
<journal-title-group>
<journal-title>Current behavioral neuroscience reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2196-2979</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28093577</article-id>
<article-id pub-id-type="pmc">5235359</article-id>
<article-id pub-id-type="doi">10.1007/s40473-016-0083-4</article-id>
<article-id pub-id-type="manuscript">NIHMS836826</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epigenetic Research in Neuropsychiatric Disorders: the “Tissue Issue”</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bakulski</surname>
<given-names>Kelly M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Halladay</surname>
<given-names>Alycia</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Valerie W.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mill</surname>
<given-names>Jonathan</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fallin</surname>
<given-names>M. Daniele</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
<!--<email>dfallin@jhu.edu</email>-->
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA</aff>
<aff id="A2"><label>2</label>Autism Science Foundation, New York City, New York, USA</aff>
<aff id="A3"><label>3</label>Department of Pharmacology and Toxicology, Rutgers University, New Brunswick, New Jersey, USA</aff>
<aff id="A4"><label>4</label>Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA</aff>
<aff id="A5"><label>5</label>University of Exeter Medical School, University of Exeter, Exeter, UK</aff>
<aff id="A6"><label>6</label>Institute for Psychiatry, Psychology and Neuroscience, King’s College London, London, UK</aff>
<aff id="A7"><label>7</label>Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA</aff>
<aff id="A8"><label>8</label>Wendy Klag Center for Autism and Developmental Disabilities, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA</aff>
<author-notes>
<fn fn-type="COI-statement" id="FN1">
<p>
<bold>Compliance with Ethical Standards</bold>
</p>
<p>
<bold>Conflict of Interest</bold>
</p>
<p>Dr. Kelly M. Bakulski, Dr. Alycia Halladay, Dr. Valerie W. Hu, Dr. Jonathan Mill, and Dr. M. Daniele Fallin declare that they have no conflict of interest.</p>
<p>
<bold>Human and Animal Rights and Informed Consent</bold>
</p>
<p>This article does not contain any studies with human or animal subjects performed by any of the authors.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>2</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>9</month>
<year>2017</year>
</pub-date>
<volume>3</volume>
<issue>3</issue>
<fpage>264</fpage>
<lpage>274</lpage>
<!--elocation-id from pubmed: 10.1007/s40473-016-0083-4-->
<self-uri xlink:href="http://link.springer.com/article/10.1007%2Fs40473-016-0083-4"></self-uri>
<abstract>
<sec id="S1">
<title>Purpose of Review</title>
<p id="P1">Evidence has linked neuropsychiatric disorders with epigenetic marks as either a biomarker of disease, biomarker of exposure, or mechanism of disease processes. Neuropsychiatric epidemiologic studies using either target brain tissue or surrogate blood tissue each have methodological challenges and distinct advantages.</p>
</sec>
<sec id="S2">
<title>Recent findings</title>
<p id="P2">Brain tissue studies are challenged by small sample sizes of cases and controls, incomplete phenotyping, post-mortem timing, and cellular heterogeneity, but the use of a primary disease relevant tissue is critical. Blood-based studies have access to much larger sample sizes and more replication opportunities, as well as the potential for longitudinal measurements, both prior to onset and during the course of treatments. Yet, blood studies also are challenged by cell-type heterogeneity, and many question the validity of using peripheral tissues as a brain biomarker. Emerging evidence suggests that these limitations to blood-based epigenetic studies are surmountable, but confirmation in target tissue remains important.</p>
</sec>
<sec id="S3">
<title>Summary</title>
<p id="P3">Epigenetic mechanisms have the potential to help elucidate biology connecting experiential risk factors with neuropsychiatric disease manifestation. Cross-tissue studies as well as advanced epidemiologic methods should be employed to more effectively conduct neuropsychiatric epigenetic research.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Neuropsychiatric disorders</kwd>
<kwd>DNA methylation</kwd>
<kwd>Epigenetics</kwd>
<kwd>Tissue</kwd>
<kwd>Blood</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>